PatentJun 18, 2026, 07:56 AM
Clearmind Medicine Granted US Patent for Binge Behavior Regulators
AI Summary
Clearmind Medicine Inc. announced it has been granted U.S. Patent No. 12,350,242, titled "BINGE BEHAVIOR REGULATORS," by the United States Patent and Trademark Office (USPTO). The patent covers innovative compositions and methods utilizing its MEAI molecule to regulate binge behaviors, including excessive drinking, eating, and gambling. This milestone expands Clearmind's global patent portfolio to 32 granted patents, reinforcing its leadership in psychedelic-based therapies and advancing clinical programs for binge-related disorders.
Key Highlights
- Granted U.S. Patent No. 12,350,242 by the USPTO.
- Patent is titled "BINGE BEHAVIOR REGULATORS".
- Covers innovative compositions and methods utilizing the MEAI molecule.
- Aims to regulate binge behaviors including excessive drinking, eating, and gambling.
- Increases Clearmind's global patent portfolio to 32 granted patents.
- Reinforces leadership in psychedelic-based therapies and advances clinical programs.
Price Impact
More from CMND